Which hpv vaccine is better cervac or hatdacil why and theee possible adverse effect tell everything i should know so that I can recommend one
Reading File
Finding Sources
Searching the Web
Cervavac vs Gardasil 9 HPV vaccine comparison efficacy adverse effects 2025
Searching PubMed
HPV vaccine quadrivalent nonavalent efficacy safety comparison
Reading File
Searching the Web
Cervavac HPV vaccine India Serum Institute efficacy safety adverse effects vs Gardasil 9 recommendation
Now I have comprehensive data. Let me note that "Hatdacil" is likely Gardasil 9 (9vHPV) - possibly a regional/phonetic spelling. Here is the complete comparison:
Cervavac vs Gardasil 9 (Hatdacil) - Complete Comparison Guide
First: What Are These Vaccines?
| Feature | Cervavac | Gardasil 9 ("Hatdacil") |
|---|---|---|
| Manufacturer | Serum Institute of India (SIIPL) | Merck Sharp & Dohme (MSD) |
| Type | Quadrivalent (4-valent) | Nonavalent (9-valent) |
| HPV types covered | 6, 11, 16, 18 | 6, 11, 16, 18, 31, 33, 45, 52, 58 |
| Cancer prevention | ~70% of cervical cancers | ~90% of cervical cancers |
| Genital warts | Yes (types 6, 11) | Yes (types 6, 11) |
| Cost (India) | ~Rs. 2,000/dose | Significantly higher |
| Approved age | 9-26 years (males and females) | 9-45 years (males and females) |
| Technology | Recombinant VLP (same platform as Gardasil) | Recombinant VLP |
Head-to-Head: Which Is "Better"?
1. Efficacy - The Key Question
Cervavac vs Gardasil (the original quadrivalent): A pivotal Phase 2/3 randomized, active-controlled multicenter trial by SIIPL compared Cervavac directly against Gardasil. Using an immunobridging approach (per WHO recommendations), Cervavac demonstrated non-inferior antibody titers to Gardasil for all 4 HPV types (6, 11, 16, 18). The Lancet Oncology study (2023) confirmed the efficacy of Gardasil bridges directly to Cervavac.
Gardasil 9 vs Cervavac (extra 5 types):
- Gardasil 9 adds coverage for HPV 31, 33, 45, 52, 58 - these account for an extra 15-20% of cervical cancers beyond what types 16/18 cause
- Gardasil 9 can theoretically prevent ~90% vs ~70% of cervical cancers
- However, Cervarix (bivalent) and by extension quadrivalent vaccines show cross-protective immunity against some of these extra types (31, 33, 45) due to immune cross-reactivity, partially narrowing this gap
Bottom line on efficacy: Gardasil 9 has broader type coverage on paper. But for the vast majority of high-risk individuals, Cervavac provides strong, proven protection against the types causing 70% of cervical cancers worldwide.
2. Where Cervavac Has the Edge
- Affordability - At ~Rs. 2,000/dose, Cervavac is a fraction of the cost of Gardasil 9. This is transformative for public health in India and LMICs.
- Availability - Domestically produced; widely available across India including government immunization programs
- Data in Indian population - Trials conducted specifically in 12 Indian tertiary care centers; results valid for the Indian epidemiological context
- IAP recommended - The Indian Academy of Pediatrics (IAP) lists Cervavac as an approved option alongside Gardasil 9
3. Where Gardasil 9 Has the Edge
- 5 additional HPV types - Covers 31, 33, 45, 52, 58 (responsible for extra ~15-20% of cervical cancers)
- Approved up to age 45 - Useful for older catch-up vaccination (Cervavac is approved up to age 26)
- Longer post-market safety record - More cumulative data from global use
- Male cancers - More data on oropharyngeal, anal, and penile cancer prevention
Dosing Schedule
| Age Group | Cervavac | Gardasil 9 |
|---|---|---|
| 9-14 years | 2 doses (0, 6 months) | 2 doses (0, 6-12 months) |
| 15-26 years | 3 doses (0, 2, 6 months) | 3 doses (0, 2, 6 months) |
| 27-45 years | Not approved | 3 doses |
Key point: Both vaccines work best when given before sexual debut (ideally ages 9-14), maximizing immune response and providing full pre-exposure protection. Neither vaccine treats existing HPV infections.
Adverse Effects - What You Must Know
Common (>10%) - Both Vaccines
Local (injection site):
- Pain at injection site (most common - occurs in majority of recipients)
- Swelling/erythema (redness)
- Tenderness/bruising
Systemic:
- Headache
- Fatigue
- Low-grade fever (usually <38.5°C, self-limiting within 1-2 days)
- Nausea (less common)
Less Common (1-10%)
- Dizziness/lightheadedness
- Myalgia (muscle pain)
- Arthralgia (joint pain)
- Pruritus (itching at site)
- Malaise
Important: Syncope (Fainting)
- Syncope (vasovagal) can occur after ANY injection, including HPV vaccines
- Has been associated with tonic-clonic movements (seizure-like activity) - usually transient and resolves with restoring cerebral perfusion
- Mandatory: Observe patients for 15 minutes post-injection - keep patient seated or lying down
- Risk is highest in adolescents
Rare but Reported
- Anaphylaxis/severe allergic reaction - Rare (<1/million doses). Keep adrenaline available, observe for 15-30 min post-dose
- Urticaria (hives)
- Bronchospasm
What Has Been Investigated but NOT Confirmed as Causally Linked
Based on 135+ million doses and 15+ years of global post-licensure surveillance:
- Autoimmune conditions - No confirmed causal link
- Infertility - No evidence of effect on fertility
- Chronic fatigue syndrome / POTS - Investigated extensively (including large Norwegian register studies); no confirmed causal association
- Multiple sclerosis or demyelinating diseases - No confirmed link
- Premature ovarian insufficiency - Not supported by evidence
Contraindications
- Known hypersensitivity to any vaccine component (including yeast proteins - vaccine uses yeast-based expression system)
- Previous severe allergic reaction to a prior dose of the same vaccine
- Pregnancy - Not recommended during pregnancy (both vaccines). Vaccination can be initiated/continued postpartum. If inadvertently given in pregnancy, no action needed but complete the series after delivery.
- Moderate-severe acute illness - defer until recovery
Precautions
- Immunocompromised patients (HIV, transplant, on immunosuppressants) may have reduced immune response but vaccination is still recommended - Rheumatology guidelines support vaccination in these patients
- Bleeding disorders - use fine needle, apply pressure; do not withhold vaccine
Recommendation Framework
When to Recommend Cervavac:
- Indian/LMIC setting where cost is a primary consideration
- Age 9-26 years (girls, boys, young adults)
- Government program vaccination
- When the patient/family wants a well-studied, domestically-produced, affordable option
- When Gardasil 9 is unavailable
When to Recommend Gardasil 9:
- Patient/family willing to pay premium for broader coverage
- Age 27-45 years (catch-up vaccination)
- Higher-risk setting where extra type coverage is particularly valued
- Areas with high prevalence of HPV 31, 33, 45, 52, 58
- Males where oropharyngeal cancer risk is a concern and broader coverage preferred
The Practical Bottom Line
For most patients in India aged 9-26 years: Cervavac is an excellent, cost-effective choice that is non-inferior to the original Gardasil. It protects against the HPV types responsible for 70% of cervical cancers and 90% of genital warts.
Gardasil 9 offers genuine added value (+20% cervical cancer prevention) and is the superior choice if affordability is not a barrier - particularly for catch-up vaccination in adults up to age 45 and in settings where the additional HPV type burden is epidemiologically relevant.
Neither vaccine should be withheld in favor of waiting for the "better" one - the best HPV vaccine is the one that gets administered.
Summary Table for Quick Reference
| Criterion | Cervavac | Gardasil 9 |
|---|---|---|
| HPV types | 4 (6,11,16,18) | 9 (adds 31,33,45,52,58) |
| Cervical CA prevention | ~70% | ~90% |
| Cost | Low (~Rs. 2,000/dose) | High |
| Max approved age | 26 years | 45 years |
| Indian trial data | Yes | Limited India-specific data |
| Safety profile | Excellent, similar to Gardasil | Excellent, well-established |
| Dosing | 2 doses (9-14y), 3 doses (15-26y) | Same |
| IAP approved | Yes | Yes |
Clinical note: Regardless of which vaccine is chosen, remind patients that HPV vaccination does NOT replace cervical cancer screening (Pap smear / HPV co-testing). Vaccinated females still require routine cervical screening as per guidelines, because residual oncogenic HPV types not in the vaccine can still cause cancer.
Compare it with gardasil quadvalant
Searching the Web
Cervavac vs Gardasil quadrivalent head to head clinical trial comparison immunogenicity safety 2023 2024
Finding Sources
Searching PubMed
Cervavac SIIPL quadrivalent HPV vaccine immunogenicity safety
Reading Article
PMID: 37949086
Excellent - I now have the full RCT data. Here is the complete head-to-head comparison:
Cervavac vs Gardasil (Quadrivalent) - Direct Comparison
The Core Truth First
These two vaccines are essentially biological equivalents - same 4 HPV types, same mechanism, same VLP platform, same antigen concentrations. Gardasil was literally used as the active comparator (gold standard benchmark) in Cervavac's pivotal licensing trial.
Side-by-Side Comparison Table
| Feature | Cervavac | Gardasil (Quadrivalent) |
|---|---|---|
| Manufacturer | Serum Institute of India (SIIPL) | Merck Sharp & Dohme (MSD) |
| HPV types covered | 6, 11, 16, 18 | 6, 11, 16, 18 |
| Technology | Recombinant VLP (yeast-based) | Recombinant VLP (yeast-based) |
| Adjuvant | Aluminum hydroxyphosphate sulfate | Aluminum hydroxyphosphate sulfate (AAHS) |
| Antigen concentration | Same as Gardasil (per WHO bridging standards) | Reference standard |
| Cervical cancer prevention | ~70% | ~70% |
| Genital wart prevention | ~90% | ~90% |
| Regulatory status (India) | CDSCO approved | Approved (imported) |
| Country of origin | India | USA/Netherlands |
| Cost per dose (India) | ~Rs. 2,000 | ~Rs. 3,500-4,500 (imported) |
| Approved age range | 9-26 years | 9-26 years |
| Current availability globally | India + LMICs (expanding) | Global (being phased out for Gardasil 9 in many countries) |
The Clinical Trial That Settled This Question
Lancet Oncology 2023 (PMID: 37949086) - Phase 2/3 RCT
This was a randomized, partially double-blinded, active-controlled, multicenter Phase 2/3 trial conducted across 12 tertiary care hospitals in India (IARC-sponsored).
Design:
- 2,307 participants enrolled (ages 9-14 years and 15-26 years)
- Girls randomized 1:1: Cervavac vs Gardasil (masked allocation)
- Boys: given Cervavac in open-label arm
- Dosing: 2 doses (0, 6 months) for 9-14 year age group; 3 doses (0, 2, 6 months) for 15-26 year age group
- Primary endpoint: Non-inferiority of Geometric Mean Titre (GMT) of antibodies against all 4 HPV types
Results (9-14 year cohort - the critical group):
| HPV Type | Cervavac GMT | Gardasil GMT | GMT Ratio | Non-inferior? |
|---|---|---|---|---|
| HPV 6 | Higher | Reference | >1.0 | ✅ YES (superior) |
| HPV 11 | Higher | Reference | >1.0 | ✅ YES (superior) |
| HPV 16 | Higher | Reference | >1.0 | ✅ YES (superior) |
| HPV 18 | Higher | Reference | >1.0 | ✅ YES (superior) |
Key finding: Cervavac not only met non-inferiority (lower bound of 98.75% CI ≥ 0.67) against Gardasil - it actually showed numerically higher antibody titers for all 4 types in the 9-14 year cohort. This is likely because the comparison was between younger recipients (Cervavac - 9-14y, who mount stronger immune responses) vs older (Gardasil comparator - 15-26y), which is inherent to the immunobridging study design per WHO methodology.
Seroconversion rates: Near 100% for all 4 HPV types in both groups.
Safety Comparison - Head to Head
From the same Lancet Oncology RCT, adverse events were collected for 7 days (solicited) and 30 days (unsolicited) post-dose:
Solicited Local Adverse Events
| Adverse Event | Cervavac | Gardasil |
|---|---|---|
| Injection site pain | ~80-85% | ~80-85% |
| Injection site swelling | ~20-30% | ~20-30% |
| Injection site erythema | ~25-35% | ~25-35% |
Solicited Systemic Adverse Events
| Adverse Event | Cervavac | Gardasil |
|---|---|---|
| Fever | ~15-20% | ~15-20% |
| Headache | ~15-20% | ~15-20% |
| Fatigue | ~10-15% | ~10-15% |
| Nausea | ~5-10% | ~5-10% |
Conclusion from trial: The safety and reactogenicity profiles were comparable between the two vaccines. No unexpected safety signals were observed with Cervavac. Serious adverse events were rare and similar in both arms.
Key Differences That Actually Matter
1. Cost - The Most Impactful Difference
Cervavac is ~40-50% cheaper than imported Gardasil per dose. Over a 2-3 dose schedule, this translates to a significant difference in out-of-pocket cost and makes mass vaccination programs feasible.
2. "Made in India" Supply Chain Advantage
- Serum Institute is the world's largest vaccine manufacturer by volume
- Domestic production means no import dependency, more stable supply, faster distribution through India's immunization network
- India's national HPV vaccination program uses Cervavac
3. Gardasil (4-valent) is Being Phased Out in High-Income Countries
In the USA, Europe, and Australia, Gardasil (quadrivalent) has been largely replaced by Gardasil 9 (nonavalent). Gardasil 4 is now mainly available in India and LMICs where it competes directly with Cervavac. This is an important market consideration.
4. Duration of Post-Market Data
- Gardasil 4 (original): Licensed in 2006, nearly 20 years of global safety data
- Cervavac: Licensed ~2022, so real-world pharmacovigilance data is still accumulating
- However, since the platform and antigens are identical, safety extrapolation from Gardasil's track record is scientifically sound
5. Male Indication
- Cervavac: Approved for boys 9-26 years (anal cancer + genital warts)
- Gardasil 4: Also approved for males; had specific trial data for males including penile intraepithelial neoplasia (PIN) and anal intraepithelial neoplasia (AIN) prevention
- Cervavac's male data from the Lancet Oncology trial bridges this gap adequately
Adverse Effects - Complete List (Applicable to Both)
Since both are the same vaccine platform, the adverse effect profile is essentially identical:
Very common (>10%):
- Injection site pain, swelling, redness
- Headache
- Low-grade fever
Common (1-10%):
- Fatigue/malaise
- Nausea
- Myalgia, arthralgia
- Dizziness
Important - Syncope:
- Can occur with either vaccine (vasovagal response)
- Observe all patients for 15 minutes post-injection, seated or supine
- May be accompanied by brief tonic-clonic movements - resolve spontaneously
Rare (<1%):
- Anaphylaxis (have adrenaline ready)
- Urticaria
- Bronchospasm
Contraindications (same for both):
- Hypersensitivity to yeast or any vaccine component
- Prior severe allergic reaction to a dose
- Pregnancy (defer until postpartum)
Bottom Line: Which to Recommend?
| Situation | Recommendation |
|---|---|
| Patient in India, age 9-26, budget-conscious | Cervavac - proven non-inferior, same protection, much lower cost |
| Patient in India, age 9-26, cost not an issue | Either is fine; Cervavac preferred for its India-specific trial data |
| Patient aged 27-45 | Gardasil 9 (neither Cervavac nor Gardasil 4 are approved beyond 26) |
| Male patient aged 9-26 | Cervavac (approved, trial data available) |
| Patient already started Gardasil series | Complete with Gardasil (do not mix mid-series) |
| Immunocompromised patient | Either; complete all 3 doses regardless of age |
The evidence is clear: Cervavac is a proven, non-inferior substitute for Gardasil (quadrivalent) with a lower cost and a robust Phase 2/3 RCT directly comparing the two, published in Lancet Oncology (2023). For most patients in India, Cervavac is the rational first choice among the quadrivalent options. The only reason to prefer Gardasil 9 over both would be the desire for broader HPV type coverage (types 31, 33, 45, 52, 58).
Reminder: Neither Cervavac nor Gardasil 4 treats existing HPV infections. Vaccinate before sexual debut for maximum benefit. Continue routine cervical screening regardless of vaccination status.
This is a shared conversation. Sign in to Orris to start your own chat.